应用新型多参数流式细胞术快速评估浆细胞疾病中的超二倍体
该研究纳入1703例浆细胞疾病患者,比较PCPRO流式细胞术与FISH检测超二倍体的一致性。PCPRO检测超二倍体灵敏度86%、特异度84%,对新诊断骨髓瘤患者,PCPRO超二倍体者总生存和无进展生存均优于非超二倍体者。
要点
- PCPRO流式检测超二倍体灵敏度86%(621/725),特异度84%(730/865)。
- 新诊断骨髓瘤中,PCPRO超二倍体者中位总生存未达到,非超二倍体者59个月(P=0.008)。
- 高超二倍体(DNA指数1.19-1.50)较低超二倍体(DNA指数1.05-1.18)3年总生存更优(88% vs 68%,P=0.03)。
核心结论
- 流式细胞术评估DNA倍体可快速提供有价值的预后信息,并减少所需拷贝数FISH探针数量从而降低FISH成本。
研究设计与样本
- 研究纳入1703例浆细胞疾病患者,同时用PCPRO(多参数流式细胞术估算DNA指数)和FISH评估单克隆浆细胞DNA倍体。
主要发现
- 倍体分布:超二倍体759例(45%),二倍体765例(45%),亚二倍体71例(4%),四倍体/近四倍体108例(6%)。
- PCPRO超二倍体患者中82%(621/756)FISH检出三体;PCPRO非超二倍体患者中88%(730/834)FISH未检出三体。
- PCPRO非超二倍体患者中95%(795/834)FISH三体≤1个。
- PCPRO检测超二倍体灵敏度86%(621/725),特异度84%(730/865);三体>1个者灵敏度94%(579/618)。
- 新诊断MM中,PCPRO超二倍体者(147/275)较非超二倍体者总生存更优(中位未达到 vs 59个月,P=0.008),无进展生存也更优(中位33 vs 23个月,P=0.03)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Trisomies of odd numbered chromosomes are seen in nearly half of patients with multiple myeloma (MM) and typically correlate with a hyperdiploid state and better overall survival (OS). We compared DNA ploidy of monoclonal plasma cells (as a surrogate for the presence of trisomies) assessed simultaneously by PCPRO (plasma cell proliferative index), a novel method that estimates DNA index by multi-parametric flow cytometry to fluorescence in situ hybridization (FISH) in 1703 patients with plasma cell disorders. The distribution of ploidy was hyperdiploid: 759 (45%), diploid 765 (45%), hypodiploid: 71 (4%), tetraploid/near-tetraploid: 108 (6%). FISH identified trisomies in 82% (621/756) of patients with hyperdiploidy by PCPRO and no trisomy by FISH was observed in 88% (730/834) of patients without hyperdiploidy. 95% (795/834) of patients without hyperdiploidy on PCPRO had one or less trisomy by FISH. Sensitivity and specificity of PCPRO for detecting hyperdiploidy was 86% (621/725) and 84% (730/865), respectively. Sensitivity increased to 94% (579/618) for patients with more than one trisomy. Newly diagnosed MM patients with hyperdiploidy on PCPRO (147/275) had better OS compared to nonhyperdiploid patients (median not reached vs 59 months, P = 0.008) and better progression free survival (median: 33 vs 23 months, P = 0.03). Within the hyperdiploidy group, patients with high-hyperdiploidy (DNA index: 1.19-1.50) versus those with low-hyperdiploidy (DNA index: 1.05-1.18) had superior OS (3 year OS of 88% vs 68% P = 0.03). Ploidy assessment by flow cytometry can provide rapid, valuable prognostic information and also reduces the number of copy number FISH probes required and hence the cost of FISH.
引用
- Sidana S, Jevremovic D, Ketterling RP, et al. Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. Am J Hematol. 2019. PMID: 30592078. doi:10.1002/ajh.25391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。